Novo Nordisk Loses Motion to Stop Eli Lilly Ads
A U.S. judge rejected Novo Nordisk's request to halt Eli Lilly's advertisements for Zepbound and Mounjaro, ruling that the company failed to prove it suffered irreparable harm.
U.S. District Judge Zahid Quraishi in Trenton, New Jersey, rejected Novo Nordisk's request for a preliminary injunction to stop Eli Lilly's advertisements for Zepbound and Mounjaro, as reported by Bitget News on October 27, 2026.
The court concluded that Novo Nordisk failed to prove it suffered irreparable harm, and that monetary compensation could address any potential harm.
The decision comes as part of a lawsuit regarding misleading advertising and unfair competition, without yet settling the merits of these claims.
The ruling allows Eli Lilly to continue its advertisements for the mentioned products pending a resolution on the merits of the dispute.
What Do These Terms Mean?
Preliminary Injunction: A temporary court decision to prevent a party from taking a specific action until the final resolution of the lawsuit.
Irreparable Harm: Harm for which financial damages are insufficient to remedy, serving as an essential condition for obtaining a preliminary injunction.
Unfair Competition: Commercial behavior that harms a competitor through unfair means, such as misleading advertising.
Weekly Newsletter
Read between the lines before everyone else. Decode the most important economic, tech, and decision-maker movements in the region.. in 5 minutes every Saturday.
